Combination therapy of resistant warts in a patient with AIDS

T. R. Roark, A. G. Pandya

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

BACKGROUND. An AIDS patient on anti-HIV therapy consisting of two reverse transcriptase inhibitors had a low CD4+ lymphocyte count, a high HIV viral RNA load, and facial warts that were resistant to ablative therapy. OBJECTIVE. To find a regimen to treat resistant warts in an AIDS patient with a depressed CD4 count and high HIV viral load. METHODS. A protease inhibitors was added to his regimen and he was treated with ablative therapy using a 585 nm flashlamp-pumped pulsed dye laser (FPPDL). RESULTS. Observed resolution of the warts one month later, with no recurrence at seven-month follow-up. CONCLUSIONS. Treatment of resistant warts in patients with AIDS may be enhanced by triple-drug therapy which includes a protease inhibitor, used in combination with ablative therapy, such as the FPPDL.

Original languageEnglish (US)
Pages (from-to)1387-1389
Number of pages3
JournalDermatologic Surgery
Volume24
Issue number12
StatePublished - 1998

Fingerprint

Warts
Acquired Immunodeficiency Syndrome
Dye Lasers
HIV
CD4 Lymphocyte Count
Protease Inhibitors
Viral Load
Therapeutics
Reverse Transcriptase Inhibitors
Viral RNA
Recurrence
Drug Therapy

ASJC Scopus subject areas

  • Dermatology
  • Surgery

Cite this

Combination therapy of resistant warts in a patient with AIDS. / Roark, T. R.; Pandya, A. G.

In: Dermatologic Surgery, Vol. 24, No. 12, 1998, p. 1387-1389.

Research output: Contribution to journalArticle

@article{60b9c6892ba34fa392513e693681a19c,
title = "Combination therapy of resistant warts in a patient with AIDS",
abstract = "BACKGROUND. An AIDS patient on anti-HIV therapy consisting of two reverse transcriptase inhibitors had a low CD4+ lymphocyte count, a high HIV viral RNA load, and facial warts that were resistant to ablative therapy. OBJECTIVE. To find a regimen to treat resistant warts in an AIDS patient with a depressed CD4 count and high HIV viral load. METHODS. A protease inhibitors was added to his regimen and he was treated with ablative therapy using a 585 nm flashlamp-pumped pulsed dye laser (FPPDL). RESULTS. Observed resolution of the warts one month later, with no recurrence at seven-month follow-up. CONCLUSIONS. Treatment of resistant warts in patients with AIDS may be enhanced by triple-drug therapy which includes a protease inhibitor, used in combination with ablative therapy, such as the FPPDL.",
author = "Roark, {T. R.} and Pandya, {A. G.}",
year = "1998",
language = "English (US)",
volume = "24",
pages = "1387--1389",
journal = "Dermatologic Surgery",
issn = "1076-0512",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Combination therapy of resistant warts in a patient with AIDS

AU - Roark, T. R.

AU - Pandya, A. G.

PY - 1998

Y1 - 1998

N2 - BACKGROUND. An AIDS patient on anti-HIV therapy consisting of two reverse transcriptase inhibitors had a low CD4+ lymphocyte count, a high HIV viral RNA load, and facial warts that were resistant to ablative therapy. OBJECTIVE. To find a regimen to treat resistant warts in an AIDS patient with a depressed CD4 count and high HIV viral load. METHODS. A protease inhibitors was added to his regimen and he was treated with ablative therapy using a 585 nm flashlamp-pumped pulsed dye laser (FPPDL). RESULTS. Observed resolution of the warts one month later, with no recurrence at seven-month follow-up. CONCLUSIONS. Treatment of resistant warts in patients with AIDS may be enhanced by triple-drug therapy which includes a protease inhibitor, used in combination with ablative therapy, such as the FPPDL.

AB - BACKGROUND. An AIDS patient on anti-HIV therapy consisting of two reverse transcriptase inhibitors had a low CD4+ lymphocyte count, a high HIV viral RNA load, and facial warts that were resistant to ablative therapy. OBJECTIVE. To find a regimen to treat resistant warts in an AIDS patient with a depressed CD4 count and high HIV viral load. METHODS. A protease inhibitors was added to his regimen and he was treated with ablative therapy using a 585 nm flashlamp-pumped pulsed dye laser (FPPDL). RESULTS. Observed resolution of the warts one month later, with no recurrence at seven-month follow-up. CONCLUSIONS. Treatment of resistant warts in patients with AIDS may be enhanced by triple-drug therapy which includes a protease inhibitor, used in combination with ablative therapy, such as the FPPDL.

UR - http://www.scopus.com/inward/record.url?scp=0032429057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032429057&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 1387

EP - 1389

JO - Dermatologic Surgery

JF - Dermatologic Surgery

SN - 1076-0512

IS - 12

ER -